Want to see FR:CLARI full AI Analyst Report?
Top Page
Clariane
(CLARI)
Select Model
Select Model
Rating:49Neutral
Price Target:
€4.00
▲(5.26% Upside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by elevated and worsening leverage alongside weak/volatile net profitability, despite strong and consistent operating/free cash flow and solid revenue growth. Technical indicators are broadly neutral with slightly negative momentum, while valuation is a clear headwind given the very high P/E and no dividend yield provided.
Positive Factors
Strong Revenue Growth
Sustained revenue expansion indicates growing demand across Clariane’s care services. Exposure to recurring residential, clinical, and home-care activity can support continued top-line growth as healthcare needs rise.
Negative Factors
Elevated and Rising Leverage
Higher leverage increases Clariane’s sensitivity to refinancing costs, interest rates, and operating volatility. It can restrict investment flexibility and leave less cash available for expansion or unexpected regulatory and staffing pressures.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained revenue expansion indicates growing demand across Clariane’s care services. Exposure to recurring residential, clinical, and home-care activity can support continued top-line growth as healthcare needs rise.
Read all positive factors
Clariane (CLARI) vs. iShares MSCI France ETF (EWQ)
Market Cap
€1.42B
Dividend Yield5.75%
Average Volume (3M)326.37K
Price to Earnings (P/E)99.5
Beta (1Y)1.20
Revenue Growth0.99%
EPS GrowthN/A
CountryFR
Employees70,685
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.04
Shares Outstanding357,540,860
10 Day Avg. Volume397,563
30 Day Avg. Volume326,371
Financial Highlights & Ratios
PEG Ratio-8.51
Price to Book (P/B)0.39
Price to Sales (P/S)0.26
P/FCF Ratio2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.41
Revenue Forecast (FY)€5.39B
Clariane Business Overview & Revenue Model
Company Description
Clariane SE, established in Paris, France, in 2001 and known as Korian until its rebranding in June 2023, specializes in delivering comprehensive medical and non-medical care and support. The company serves senior citizens and individuals facing e...
How the Company Makes Money
Clariane makes money primarily by providing care services to residents and patients and being paid for those services through a mix of public funding and private pay, depending on the country, care setting, and type of service.
Key revenue stream...
Clariane Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
38
Negative
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.35B | 5.31B | 5.28B | 5.00B | 4.44B | 4.14B |
| Gross Profit | 143.02M | 431.50M | 4.84B | 1.57B | 4.09B | 3.83B |
| EBITDA | 748.75M | 1.01B | 1.01B | 952.04M | 907.45M | 946.76M |
| Net Income | 12.61M | 1.60M | -55.12M | -105.25M | 22.06M | 91.11M |
Balance Sheet | ||||||
| Total Assets | 14.36B | 13.81B | 14.26B | 15.18B | 14.57B | 14.31B |
| Cash, Cash Equivalents and Short-Term Investments | 1.42B | 821.56M | 518.10M | 677.91M | 734.35M | 1.22B |
| Total Debt | 8.35B | 7.81B | 7.98B | 8.55B | 8.27B | 8.23B |
| Total Liabilities | 10.44B | 9.89B | 10.24B | 11.24B | 10.71B | 10.54B |
| Stockholders Equity | 3.62B | 3.61B | 3.69B | 3.58B | 3.54B | 3.49B |
Cash Flow | ||||||
| Free Cash Flow | 570.87M | 577.76M | 600.10M | 320.04M | 116.36M | 311.05M |
| Operating Cash Flow | 801.77M | 796.46M | 908.13M | 804.15M | 681.66M | 839.97M |
| Investing Cash Flow | 180.84M | 137.55M | 47.69M | -669.52M | -770.26M | -825.28M |
| Financing Cash Flow | -321.59M | -670.90M | -1.11B | -193.61M | -550.13M | 31.38M |
Clariane Technical Analysis
Neutral
3.80
Price Trends
4.03
Negative
4.05
Negative
3.92
Positive
Market Momentum
-0.02
Negative
48.87
Neutral
70.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:CLARI, the sentiment is Neutral. The current price of 3.8 is below the 20-day moving average (MA) of 4.00, below the 50-day MA of 4.03, and below the 200-day MA of 3.92, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.87 is Neutral, neither overbought nor oversold. The STOCH value of 70.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:CLARI.
Clariane Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | €338.66M | 13.83 | 7.44% | 2.92% | 13.15% | 10.30% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €2.07B | -7.82 | -15.35% | 0.84% | 3.92% | 31.20% | |
49 Neutral | €1.42B | 99.50 | 0.35% | 5.75% | 0.99% | ― | |
49 Neutral | €160.89M | 5.50 | 33.68% | 0.58% | -11.89% | 1623.56% | |
49 Neutral | €1.18B | -20.48 | -4.25% | 11.04% | 2.65% | 10.24% |
* General Sector Average
FR:CLARI
Clariane
3.98
0.07
1.89%
FR:BLC
Bastide le Confort Medical
22.00
-2.05
-8.52%
FR:LNA
LNA Sante SA
32.50
3.87
13.50%
FR:EMEIS
Orpea SA
12.82
2.07
19.26%
FR:GDS
Ramsay Generale de Sante
10.70
0.70
7.00%
Clariane Corporate Events
Clariane boosts half-year earnings and secures over €1bn in refinancing
Jul 29, 2026
Clariane reported first-half 2026 revenue of €2.699bn, up 4.6% organically, driven by volumes and pricing, with pre-IFRS 16 EBITDA rising 14.9% and margin improving to 10.4%. Opco EBITDA climbed 25.1% and margin reached 6.2%, while nursing h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.